Effects of selective estrogen receptor modulators and genistein on the expression of ERα/β and COX-1/2 in ovarectomized mouse uteri

European Journal of Gynaecological Oncology

Volumn 28, Issue 2, 2007, Pages 89-94

  Wu, Y ^a   Niwa, K ^a   Onogi, K ^a   Tang, L ^a   Mori, H ^a   Tamaya, T ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

c fos jun; COX 1 2; ER ; Genistein; SERMs

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GENISTEIN; PROTEIN C FOS; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN; TOREMIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENDOMETRIUM CANCER; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIECTOMY; PROTEIN EXPRESSION; SCORING SYSTEM; UTERUS;

ANIMALS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENISTEIN; MICE; MICE, INBRED ICR; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TOREMIFENE;

EID: 34248214181     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Flototto T., Djahasouzi S., Glaser M., Hanstein B., Niederacher D., Brumm C. et al.: "Hormones and hormone antagosists: mechanisms of action in carcinogenesis of endometrial and breast cancer". Hon Metab. Res., 2001, 33, 451.
2. rd et al.: "American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition". J. Clin. Oncol., 2002, 20, 3328.
3. Bartsch H., Phillips D.H., Nair J., Hewer A., Meyberg-Solomeyer G., Grischke E.M.: "Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients" Carcinogenesis, 2000, 21, 845.
4. Niwa K., Morishita S., Hashimoto M., Itoh T., Fujimoto J., Mori H. et al.: "Effects of tamoxifen on endometrial carcinogenesis in mice". Jpn. J. Cancer Res., 1998, 89, 502.
5. Niwa K., Hashimoto M., Lian Z., Gao J., Tagami K., Yokoyama Y. et al.: "Inhibitory effects of toremifene on N-methyl-N-nitrosourea and estradiol-17β-induced endometrial carcinogenesis in mice". Jpn. J. Cancer Res., 2002, 93, 626.
6. Adamson E.D.: "Oncogenes in development". Development, 1987, 99, 449.
7. Weitz A., Bresciania F.: "Estrogen induces expression of c-fos and c-myc protooncogenes in the rat uterus". Mol. Endocrinol., 1988, 2, 816.
8. Weitz A., Cicatiell L., Persiot E., Scalona M., Bresciani F.: "Estrogen stimulation of transcription of c-jun protooncogene". Mol. Endocrinol., 1990, 4, 1031.
9. Morishta S., Niwa K., Ichigo S., Hori M., Murase T., Fujimoto J. et al.: "Overexpression of c-fos/jun mRNA and their oncoprotein (Fos/Jun) in the mouse uterus treated with three natural estrogens". Cancer Lett., 1995, 97, 225.
10. Niwa K., Hashimoto M., Morishita S., Yokoyama Y., Mori H., Tanaka T. et al.: "Enhancing effects of estrogens on endometrial carcinogenesis initiated by N-methyl-N-nitrosourea in ICR mice". Jpn. J. Cancer Res., 1993, 84, 951.
11. Gstafsson J.A.: "Estrogen receptor β. A new dimension in estrogen mechanism of action". J. Endocrinol., 1999, 163, 379.
12. Taylor A.H., Al-Azzawi F.: "Immunolocalisation of oestrogen receptor beta in human tissues". J. Mol. Endocrinol., 2000, 24, 145.
13. Kuiper G.G.J.M., Lemmen J.G., Carlsson L.B., Corton J.C., Safe S.H., van der Saag P.T. et al.: "Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β". Endocrinology, 1998, 139, 4252.
14. Bardin A., Boulle N., Lazennec G., Vignon F., Pujor P.: "Loss of ERβ expression as a common step in estrogen-dependent tumor progression". Endocr. Relat. Cancer, 2004, 11, 537.
15. Lazennec G.: "Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis". Cancer Lett., 2006, 231, 151.
16. Ferrandina G., Legge F., Ranelletti F.O., Zannoni G.F., Maggiano N., Evangelist A. et al.: "Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome". Cancer, 2002, 95, 801.
17. Jabbour H.N., Milne S.A., Williams A.R., Anderson R.A., Boddy S.C.: "Expression of COX-2 and PGE synthase and synthesis of PGE2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors". Br. J. Cancer, 2001, 85, 1023.
18. Tagami K., Niwa K., Lian Z., Gao J., Mori H., Tamaya T.: "Preventive effect of Juzen-taiho-to on endometrial carcinogenesis in mice is based on Shimotsu-to constituent". Biol. Pharm. Bull., 2004, 27, 156.
19. Chomczynski P., Sacchi N. et al.: "Single-step method of RNA isolation by acid guanitdium thiocynate-phenol-chloroform extraction". Anal. Biochem., 1987, 162, 156.
20. Hiroi H., Momoeda M., Inoue S., Tsuchiya F., Mastumi H., Tsutumi O. et al.: "Stage-specific expression of estrogen receptor subtypes and estrogen responsive finger protein in preimplantational mouse embryos". Endocr. J., 1999, 46, 153.
21. Jang M., Pezzuto J.M.: "Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin". Cancer Lett., 1998, 134, 81.
22. Giri D.D., Dangerfield V.J., Lonsdale R., Rogers K., Underwood J.C.: "Immunohistology of oestrogen receptor and D5 antigen in breast cancer: correlation with oestrogen receptor content of adjacent cryostat sections assayed by radioligand binding and enzyme immunoassay". J. Clin. Pathol., 1987, 40, 734.
23. Goulding H., Pinder S., Cannon P., Pearson D., Nicholson R., Snead D. et al.: "A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples". Hum. Pathol., 1995, 26, 291.
24. Krajewska M., Krajewski S., Epstein J.I., Shabaik A., Sauvageot J., Song K. et al.: "Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers". Am. J. Pathol., 148, 1567.
25. Fujiwaki R., Iida K., Kanasaki H., Ozaki T., Hata K., Miyazaki K.: "Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase". Hum. Pathol., 2002, 33, 213.
26. Lian Z., Niwa K., Tagami K., Hashimoto M., Gao J., Yokoyama Y. et al.: "Preventive effects of isoflavones, genistein and daidzein, on estradiol-17β-related endometrial carcinogenesis in mice". Jpn. J. Cancer Res., 2001, 92, 726.
27. Lian Z., Niwa K., Onogi K., Mori H., Harrigan R.C., Tamaya T.: "Anti-tumor effects of herbal medicines on endometrial carcinomas via estrogen receptor-alpha-related mechanism". Oncol. Rep., 2006, 15, 1133.